JP2009512705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512705A5 JP2009512705A5 JP2008536749A JP2008536749A JP2009512705A5 JP 2009512705 A5 JP2009512705 A5 JP 2009512705A5 JP 2008536749 A JP2008536749 A JP 2008536749A JP 2008536749 A JP2008536749 A JP 2008536749A JP 2009512705 A5 JP2009512705 A5 JP 2009512705A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- ester
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- -1 cachets Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/255,643 US7825121B2 (en) | 1999-05-04 | 2005-10-21 | Piperazine derivatives useful as CCR5 antagonists |
| PCT/US2006/040636 WO2007050375A2 (en) | 2005-10-21 | 2006-10-18 | Piperazine derivatives useful as ccr5 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012007201A Division JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009512705A JP2009512705A (ja) | 2009-03-26 |
| JP2009512705A5 true JP2009512705A5 (enExample) | 2012-03-22 |
Family
ID=37872167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536749A Pending JP2009512705A (ja) | 2005-10-21 | 2006-10-18 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2012007201A Pending JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012007201A Pending JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7825121B2 (enExample) |
| EP (1) | EP1951708B1 (enExample) |
| JP (2) | JP2009512705A (enExample) |
| KR (1) | KR20080058486A (enExample) |
| CN (1) | CN101326178A (enExample) |
| AR (1) | AR058105A1 (enExample) |
| AU (1) | AU2006306491B2 (enExample) |
| BR (1) | BRPI0617731A2 (enExample) |
| CA (1) | CA2626565A1 (enExample) |
| EC (1) | ECSP088378A (enExample) |
| IL (1) | IL190902A0 (enExample) |
| NO (1) | NO20082297L (enExample) |
| PE (1) | PE20070711A1 (enExample) |
| RU (1) | RU2008119652A (enExample) |
| TW (1) | TW200800234A (enExample) |
| WO (1) | WO2007050375A2 (enExample) |
| ZA (1) | ZA200803454B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2431524T3 (es) | 2004-04-13 | 2013-11-26 | Incyte Corporation | Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas |
| WO2007081597A2 (en) * | 2005-10-21 | 2007-07-19 | Glaxo Group Limited | Peri condensed tricyclic compounds useful as antibacterial agents |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| MX2013010330A (es) | 2011-03-09 | 2014-11-26 | Richard G Pestell | Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas. |
| GB201118876D0 (en) | 2011-11-01 | 2011-12-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| HK1209673A1 (en) * | 2012-05-14 | 2016-04-08 | Prostagene Llc | Using modulators of ccr5 for treating cancer |
| WO2016094011A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Crystal forms of a ccr5 antagonist |
| US12459808B2 (en) | 2021-09-13 | 2025-11-04 | Kabushiki Kaisha Toshiba | Sensor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| IL145741A0 (en) | 1999-05-04 | 2002-07-25 | Schering Corp | Piperazine derivatives useful as ccrs antagonists |
| EP1373206B1 (en) | 2001-03-29 | 2008-12-24 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
-
2005
- 2005-10-21 US US11/255,643 patent/US7825121B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 BR BRPI0617731-0A patent/BRPI0617731A2/pt not_active IP Right Cessation
- 2006-10-18 JP JP2008536749A patent/JP2009512705A/ja active Pending
- 2006-10-18 EP EP06826151.0A patent/EP1951708B1/en active Active
- 2006-10-18 CA CA002626565A patent/CA2626565A1/en not_active Abandoned
- 2006-10-18 RU RU2008119652/04A patent/RU2008119652A/ru not_active Application Discontinuation
- 2006-10-18 CN CNA2006800462485A patent/CN101326178A/zh active Pending
- 2006-10-18 AU AU2006306491A patent/AU2006306491B2/en not_active Ceased
- 2006-10-18 WO PCT/US2006/040636 patent/WO2007050375A2/en not_active Ceased
- 2006-10-18 KR KR1020087011479A patent/KR20080058486A/ko not_active Withdrawn
- 2006-10-19 AR ARP060104564A patent/AR058105A1/es not_active Application Discontinuation
- 2006-10-19 PE PE2006001267A patent/PE20070711A1/es not_active Application Discontinuation
- 2006-10-20 TW TW095138842A patent/TW200800234A/zh unknown
-
2008
- 2008-04-15 IL IL190902A patent/IL190902A0/en unknown
- 2008-04-17 EC EC2008008378A patent/ECSP088378A/es unknown
- 2008-04-18 ZA ZA200803454A patent/ZA200803454B/xx unknown
- 2008-05-20 NO NO20082297A patent/NO20082297L/no not_active Application Discontinuation
-
2012
- 2012-01-17 JP JP2012007201A patent/JP2012072195A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1104238C (zh) | 霉酚酸盐的包有肠溶衣的药物组合物 | |
| CN108042808B (zh) | 用于治疗中枢系统疾病的包含依匹哌唑或其盐和第二种药物的组合 | |
| JP5769763B2 (ja) | 治療用組成物およびその使用 | |
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| TW201023858A (en) | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside | |
| EP1940364A2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| JP2002519434A5 (enExample) | ||
| ES2318771T3 (es) | 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis. | |
| WO2012011917A1 (en) | Administration of rifalazil to immunocompromised patients | |
| TW200817052A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| JP2002502875A (ja) | 肝炎ウイルス感染症を処置するためのｎ−置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用 | |
| CN106999462A (zh) | 包含选择性s1p1受体激动剂的药物组合物 | |
| JP2009512705A5 (enExample) | ||
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| CN118845776A (zh) | 治疗丁型肝炎病毒感染 | |
| CA2577740A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| JP2009517411A5 (enExample) | ||
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| KR20190061027A (ko) | 비-알코올성 지방간 질환의 치료를 위한 약학 조성물 및 방법 | |
| WO2018115888A1 (en) | Novel formulations of aprepitant | |
| KR20180071276A (ko) | Hcv 치료를 위한 조합물 요법 투약법 | |
| JP2008534592A5 (enExample) | ||
| JP2022523668A (ja) | Ｍａｇｌ阻害剤による疾病の治療方法 | |
| WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
| TWI335219B (en) | Virus therapeutic drug |